A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP

Conditions

• HIV Infections

Interventions

• BIOLOGICAL: Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48)
• BIOLOGICAL: Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48)
• BIOLOGICAL: Vaccine Group C: Saline placebo (weeks 0,4,24,48)
• DRUG: Control PrEP:TDF/FTC once daily (weeks 0-26)
• DRUG: Experimental PrEP:TAF/FTC once daily (weeks 0-26)

Sponsor

MRC/UVRI and LSHTM Uganda Research Unit

Collaborators

• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]